IL273909B2 - Treatment of cd20-positive b-cell lymphoma with obituzumab - Google Patents

Treatment of cd20-positive b-cell lymphoma with obituzumab

Info

Publication number
IL273909B2
IL273909B2 IL273909A IL27390920A IL273909B2 IL 273909 B2 IL273909 B2 IL 273909B2 IL 273909 A IL273909 A IL 273909A IL 27390920 A IL27390920 A IL 27390920A IL 273909 B2 IL273909 B2 IL 273909B2
Authority
IL
Israel
Prior art keywords
obinutuzumab
cycle
hour
administration
pharmaceutical composition
Prior art date
Application number
IL273909A
Other languages
English (en)
Hebrew (he)
Other versions
IL273909B1 (en
IL273909A (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL273909(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL273909A publication Critical patent/IL273909A/en
Publication of IL273909B1 publication Critical patent/IL273909B1/en
Publication of IL273909B2 publication Critical patent/IL273909B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
IL273909A 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obituzumab IL273909B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Publications (3)

Publication Number Publication Date
IL273909A IL273909A (en) 2020-05-31
IL273909B1 IL273909B1 (en) 2025-08-01
IL273909B2 true IL273909B2 (en) 2025-12-01

Family

ID=64362606

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273909A IL273909B2 (en) 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obituzumab
IL321935A IL321935A (en) 2017-10-19 2018-10-19 Treatment of CD20-positive B-cell lymphoma with obinutuzumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL321935A IL321935A (en) 2017-10-19 2018-10-19 Treatment of CD20-positive B-cell lymphoma with obinutuzumab

Country Status (14)

Country Link
US (2) US12129304B2 (cg-RX-API-DMAC10.html)
EP (2) EP3697818B1 (cg-RX-API-DMAC10.html)
JP (2) JP6860652B2 (cg-RX-API-DMAC10.html)
KR (3) KR20260011191A (cg-RX-API-DMAC10.html)
CN (2) CN111212854A (cg-RX-API-DMAC10.html)
AU (2) AU2018303836B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020007731A2 (cg-RX-API-DMAC10.html)
CA (1) CA3079374A1 (cg-RX-API-DMAC10.html)
ES (1) ES3005784T3 (cg-RX-API-DMAC10.html)
IL (2) IL273909B2 (cg-RX-API-DMAC10.html)
MX (2) MX419643B (cg-RX-API-DMAC10.html)
PL (1) PL3697818T3 (cg-RX-API-DMAC10.html)
TW (2) TWI828593B (cg-RX-API-DMAC10.html)
WO (1) WO2019017499A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3697818T3 (pl) * 2017-10-19 2025-03-24 F. Hoffmann-La Roche Ag Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem
AU2020356896B2 (en) * 2019-10-04 2026-07-30 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant CD20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type II anti-CD20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
WO2023042679A1 (ja) 2021-09-17 2023-03-23 キヤノン株式会社 送電装置および受電装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024228A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
WO2009080541A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Antibody formulation
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US12377681B2 (en) 2017-07-21 2025-08-05 The Yokohama Rubber Co., Ltd. Pneumatic tire
PL3697818T3 (pl) * 2017-10-19 2025-03-24 F. Hoffmann-La Roche Ag Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024228A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUILLAUME CARTRON ET AL,, OBINUTUZUMAB (GA101) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: FINAL DATA FROM THE PHASE 1/2 GAUGUIN STUDY, 20 August 2014 (2014-08-20) *
TOBINAI KENSEI ET AL,, A REVIEW OF OBINUTUZUMAB (GA101), A NOVEL TYPE II ANTI-CD20 MONOCLONAL ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH B-CELL MALIGNANCIES, 21 December 2016 (2016-12-21) *
TSUJIMURA HIDEKI,, SAFETY AND TOLERABILITY OF OBINUTUZUMAB (GA101) WITH SHORTER DURATION OF INFUSION IN JAPANESE PATIENTS WITH PREVIOUSLY UNTREATED CD20-POSITIVE B-CELL NON-HODGKIN'S LYMPHOMA (NHL)-COMPARISON WITH GAO4915G (GATHER) AND BO21005 (GOYA) STUDIES | BLOOD JO, 2 December 2016 (2016-12-02) *

Also Published As

Publication number Publication date
WO2019017499A2 (en) 2019-01-24
MX2020003418A (es) 2020-07-20
CN120983618A (zh) 2025-11-21
TWI828593B (zh) 2024-01-01
TW202342099A (zh) 2023-11-01
JP2019528282A (ja) 2019-10-10
JP6860652B2 (ja) 2021-04-21
IL321935A (en) 2025-09-01
KR20200067196A (ko) 2020-06-11
TW201922284A (zh) 2019-06-16
JP2021152002A (ja) 2021-09-30
EP3697818B1 (en) 2024-11-27
CA3079374A1 (en) 2019-01-24
KR20240157135A (ko) 2024-10-31
IL273909B1 (en) 2025-08-01
BR112020007731A2 (pt) 2020-10-20
IL273909A (en) 2020-05-31
WO2019017499A3 (en) 2019-02-21
EP4520347A3 (en) 2025-06-04
EP4520347A2 (en) 2025-03-12
US20250026847A1 (en) 2025-01-23
MX419643B (es) 2025-01-14
KR20260011191A (ko) 2026-01-22
US12129304B2 (en) 2024-10-29
MX2024009217A (es) 2024-11-08
KR102766089B1 (ko) 2025-02-13
JP7370357B2 (ja) 2023-10-27
TWI805630B (zh) 2023-06-21
AU2025205481A1 (en) 2025-08-07
KR102906969B1 (ko) 2026-01-05
PL3697818T3 (pl) 2025-03-24
AU2018303836B2 (en) 2025-04-17
US20200299398A1 (en) 2020-09-24
ES3005784T3 (en) 2025-03-17
CN111212854A (zh) 2020-05-29
AU2018303836A1 (en) 2020-05-14
EP3697818A2 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
IL273937B2 (en) Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US20250026847A1 (en) Treatment of cd20-positive b-cell lymphoma with obinutuzumab
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
JP2026082919A (ja) 白血病またはリンパ腫の治療のためのレナリドミドと組み合わせた抗ｃｄ１９療法
Mamelak et al. Rituximab therapy in severe juvenile pemphigus vulgaris
JP2025522729A (ja) ガレクチン－９を阻害する抗体を用いた悪性血液疾患の処置
HK40031517A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
BR122025025322A2 (pt) Composição farmacêutica para o tratamento de linfoma de células b e uso do obinutuzumabe
CZ20032672A3 (cs) CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
US12599620B2 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
CA3035327C (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
EA051578B1 (ru) Терапия анти-cd19 в комбинации с леналидомидом для лечения лейкоза или лимфомы
JP2024538064A (ja) ミクログリア活性化を抑制するための方法